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Background: Previous clinical trials have demonstrated the clinical and angiographic superiority of everolimus-
eluting stents (EES) comparedwith paclitaxel-eluting stents (PES) in the small coronary vessel. However, the dif-
ferences of vascular response including assessment of morphological neointimal tissue (NIT) characteristics
using optical coherence tomography (OCT) have not been fully evaluated. The aim of this study is to evaluate
the differences of chronic vascular response following small coronary stenting between EES and PES using OCT.
Methods and results: A prospective OCT examination at 9 month follow-up was performed for 50 small coronary
artery diseases (50 patients) treated by a single 2.5 mm stent for each stent group. Cross-sectional area within
stent segments were analyzed at an interval of 1 mm. NIT structure (homogeneous or heterogeneous) was eval-
uated for qualitative assessment. Homogeneous NIT was observed signiﬁcantly higher and heterogeneous NIT
was lower in EES compared with PES (93% vs. 89%; p = 0.003, 6.5% vs. 10.3%; p = 0.002, respectively). The fre-
quencies of exposed and malapposed struts were lower in EES compared with PES (0.2% vs. 1.7%; p = 0.0001,
0.1% vs. 0.3%; p = 0.001, respectively). NIT eccentricity index and NIT area were lower in EES compared with
PES (0.69 ± 0.08 vs. 0.76 ± 0.10; p = 0.001, 0.97 ± 0.42 mm2 vs. 1.27 ± 0.67 mm2; p = 0.01, respectively).
Conclusions:A favorable vascular responsewas observed after EES implantation comparedwith PES for small cor-
onary artery disease. In addition, the characteristics of NIT after EES implantation were more stable than PES at
9 month follow-up.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Lesions in small coronary vessels comprise a challenging disease sub-
set in contemporary interventional practice. Although drug-eluting stents
(DES) have been able to strikingly reduce the rate of in-stent restenosis,
vessel size is still one of the strong independent predictors of angiograph-
ic and clinical restenosis [1]. Previous studies have been shown that an
everolimus-eluting stent (EES), a second generation DES, was superior
to a paclitaxel-eluting stent (PES) in terms of a signiﬁcant reduction of
in-stent late loss and target lesion revascularization rate in small coronary
vessels [2–4]. However, morphological differences of neointimal tissue
(NIT) have not been evaluated between these two stents. Opticalliability and freedom from bias
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nd Ltd. This is an open access article uncoherence tomography (OCT) is a novel intravascular imaging modality
that can produce in vivo high-resolution images of the coronary artery,
providing new insights into the characteristics of atherosclerotic plaques
[5–8] and NIT structure in stents [9]. The aim of this study is to evaluate
the differences of chronic vascular response following small coronary
stenting between EES and PES evaluated by OCT.
2. Material and methods
2.1. Study design and population
This study was designed as the OCT sub-analysis of SACRA (SmAll
CoronaRyArtery treated by TAXUS Liberté) andPLUM (PROMUS/Xience
V Everolimus-ELUting Coronary Stent for sMall coronary artery disease)
registries. These registries were performed consecutively. SACRA was a
prospective multi-center registry performed at 26 sites in Japan in
which 245 patients with 258 lesions were enrolled from April, 2009,
to February, 2010. PLUM was also a prospective multi-center registry
performed at the same 26 sites in which 252 patients with 266 lesions
were enrolled from March, 2010, to June, 2011. The objective of bothder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tiﬁc, Natick, MA]/XIENCE V [Abbott Vascular, Santa Clara, CA]) and PES
(TAXUS Liberte [Boston Scientiﬁc, Natick,MA]) for small coronary artery
disease. Both registries includedmales and non-pregnant females, aged
20 years or older, with evidence of myocardial ischemia. The de novo
target lesion(s) in native coronary artery had to have a reference vessel
diameter b2.5 mm by visual estimation, a target lesion length b28 mm
for single stenting, and a visually estimated stenosis of the luminal di-
ameter between 75 and 99%. Exclusion criteria were: 1) primary angio-
plasty for ST-elevationmyocardial infarction; 2) left ventricular ejection
fraction b30%; 3) other concomitant disease or medical condition that
could impact patient/procedural outcomes, such as history of bleeding
diathesis, stroke, or transient ischemic neurological attacks within the
past year; or hypersensitivity to stainless steel, everolimus, paclitaxel,
heparin, aspirin, ticlopidine, clopidogrel or X-ray contrast media; 4)
chronic total occlusion; 5) in-stent restenosis; and 6) severe vessel tor-
tuosity or calciﬁcation whichwould hinder successful stent delivery; 7)
serum creatinine level N2 mg/dl. The primary endpoint of both regis-
tries was a one year target lesion revascularization rate. In each registry,
50 consecutive patients were enrolled at two centers (Toyohashi Heart
Center, Aichi, Japan and The Cardiovascular Institute Hospital, Tokyo,
Japan) for a formal prospective sub-analysis using OCT at 9 month
follow-up angiography. The inclusion criteria of the OCT sub-analysis
were: 1) stent at the target lesion without in-stent restenosis; 2) non-
ostial lesion; 3) absence of extreme vessel tortuosity or calciﬁcation
which would hinder successful occlusion balloon catheter delivery.
The study protocol for OCT sub-analysis was approved by ethics com-
mittees in both institutions, and all eligible patients gave written in-
formed consent.
2.2. Quantitative coronary angiography
An independent core laboratory (CVIC: CardioVascular Image
Center, Toyohashi, Japan) analyzed baseline, post-procedural and 9-
month follow-up angiographic images using a validated automated
edge-detection system (QCA-CMS version 5.1, CMS-MEDIS, the
Netherlands). The core laboratory was blinded to the treatment assign-
ment. Off-line quantitative coronary analysis was performed on the
view that clearly showed the highest degree of stenosis. Quantitative
measurements were performed at baseline and post-procedure. At
follow-up angiography, quantitative parameters included the area
5 mmdistal and proximal to the stent as well as inside the stent. Binary
restenosis was deﬁned as N50% luminal diameter stenosis. In-stent late
lumen losswas deﬁned as the difference betweenminimum luminal di-
ameter post-procedure and that at 9-month follow-up angiography.
2.3. OCT imaging
After completion of coronary angiography, patients were evaluated
with OCT. OCT imaging was performed using the M2 OCT system
(LightLab Imaging; Westford, MA) and Helios occlusion balloon cathe-
ter (LightLab Imaging) method. The occlusion balloon catheter was ad-
vanced proximal to the implanted stent under the guidance of a 0.014-
in angioplasty wire, and the guide wire was then exchanged with the
OCT imagingwire, whichwas then positioned distal to the stent. During
image acquisition, lactated Ringer solution was continuously ﬂushed
through the inner lumen of the occlusion catheter at a rate of 0.5 to
1.0 ml/s by power injector, and the balloon was inﬂated to 0.4 to
0.8 atmuntil bloodﬂowwas fully occluded.Motorized pullbackOCT im-
agingwas performed at a rate of 1.0 mm/s throughout the stent. Images
were acquired at 15.6 frames/s and digitally archived.
2.4. OCT quantitative and qualitative analysis
OCT analysis was performed using LightLab Imaging proprietary
software. Both qualitative and quantitative analyses of OCT imageswere performed by independent core laboratories (CICL: Cardiovascular
Imaging Core Laboratory, Tokyo, Japan). The analyses, including lumen
and stent areas or morphological appearance, were performed at 1-
mm longitudinal steps throughout the pullback from distal stent edge
to proximal stent edge. The thickness of NIT on each stent strut was
measured. An uncovered strut was deﬁned as a strut with a measured
NIT thickness equal to 0 μm. A malapposed strut was a strut with a dis-
tance from its surface to the adjacent vessel surface more than 108 μm
in EES and more than 134 μm in PES (a total of the thickness of stent
strut and polymer layer) [10–12]. At every frame, maximum and mini-
mum thicknesses of NIT were recorded and NIT eccentricity index
([maximum − minimum thickness of NIT] / maximum thickness of
NIT) was calculated. The lumen and stent were manually traced, and
NIT area (stent area − lumen area) was calculated. Percent NIT area
was also calculated [(NIT area / stent area) × 100]. To evaluate themor-
phological appearance of NIT, the pattern of tissue structure in cross-
sectional images at every 1-mm interval was categorized as follows:
(1) homogeneous intima where tissue has uniform optical properties
and does not show focal variations in backscattering pattern (Fig. 1A)
[13]; (2) heterogeneous intima where tissue has focally changing opti-
cal properties with various backscattering patterns (Fig. 1B) or tissue
consists of signal poor area with or without adluminal high scattering
layer (Fig. 1C) [14,15]; (3) peri-stent ulcer-like appearance (Fig. 1D)
[15]; (4) visible intraluminal materials (Fig. 1E) [14]. When the reading
of the qualitative analysis by 2 observers differed, a consensus was
reached and used in the ﬁnal decision. To test the interobserver variabil-
ity of the qualitative OCT analysis, a total of 100 cross-sections within
the stent from 10 patients with 10 cross-sections each were selected
and analyzed independently by 2 observers not involved in the primary
data analysis. One of the observers repeated the analysis 2 weeks later
to assess the intraobserver variability.
2.5. Statistical analysis
Categorical variables are expressed as numbers and percentages.
Continuous variables are expressed as mean± SD ormedian and inter-
quartile ranges. Comparisons between groupswere performedwith a 2-
tailed Student t test for normally distributed variables, Mann–Whitney
U test for non-normally distributed variables, or with the chi-squared
test or Fisher exact test for categorical variables. The reproducibility of
qualitative variables was assessed with [kappa] test. SPSS 15.0 (SPSS,
Inc., Chicago, Illinois) was used for data analysis. A probability value of
less than 0.05 was considered to indicate statistical signiﬁcance.
3. Results
3.1. Clinical characteristics
A total of 50 patients were enrolled from each stent group. Clinical
characteristics, laboratory data, and medication therapies of the study
population are listed in Table 1. Dual anti-platelet therapy continued
during the follow-up period in both groups.
3.2. Lesion characteristics and procedural results
Baseline lesion characteristics and procedural results are summa-
rized in Table 2. Lesion location was similar between the two groups.
Maximum stent dilatation pressure was signiﬁcantly lower and post di-
latation was performed more frequently in the EES group.
3.3. QCA analysis
QCAﬁndings revealed no signiﬁcant differences in any parameters at
pre-procedure, post-procedure, and 9 month follow-up between the 2
groups (Table 3). Late loss was similar between the two group (EES
group vs. PES group; 0.38 ± 0.41 mm vs. 0.42 ± 0.36, p = 0.61).
Fig. 1. The morphological appearance of neointimal tissue. A. Homogeneous intima where tissue has uniform optical properties and does not show focal variations in backscattering pat-
tern. B. Heterogeneous intima where tissue has focally changing optical properties with various backscattering patterns. C. Tissue consists of signal poor area with or without adluminal
high scattering layer. D. Peri-stent ulcer-like appearance. E. Visible intraluminal materials.
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Representative examples of EES and PES groups are shown in Figs. 2
and 3, respectively. The results of OCT quantitative and qualitative anal-
ysis are shown in Table 4. At strut level, EES presented a lower percent-
age with exposed and malapposed struts than PES (exposed strut: 0.2%
vs. 1.7%; p = 0.0001, malapposed strut: 0.1% vs. 0.3%; p = 0.001). InTable 1
Baseline clinical characteristics and laboratory data.
Variable EES (n = 50) PES (n = 50) p
Age, yrs 70.5 ± 7.4 70.4 ± 8.0 0.94
Male 30 (60%) 38 (76%) 0.6
Coronary risk factors
Diabetes 18 (36%) 18 (36%) 0.13
Hypertension 27 (54%) 28 (74%) N0.99
Hyperlipidemia 20 (40%) 15 (39%) 0.4
Smoking 3 (6%) 7 (18%) 0.2
Family history
Prior MI 13 (26%) 9 (224%) 0.47
Prior PCI 22 (44%) 10 (224%) 0.02
Left ventricular EF, % 57.5 ± 10.3 54.2 ± 8.7 0.16
Total cholesterol, mg/dl 182.7 ± 29.5 185.2 ± 40.5 0.75
LDL cholesterol, mg/dl 102.5 ± 26.6 104.7 ± 31.5 0.73
HDL cholesterol, mg/dl 50.9 ± 12.8 48.0 ± 11.5 0.25
Medication
DAPT 50 (100%) 50 (100%) N0.99
ACE-I 5 (10%) 7 (14%) 0.48
Statins 28 (56%) 30 (60%) 0.84
Insulin 2 (4%) 1 (2%) N0.99
Oral hypoglycemics 16 (32%) 17 (34%) N0.99
Values are the numbers (%) or mean ± SD.
ACE-I = angiotensin converting enzyme inhibitors. EES = everolimus-eluting
stent. PES = paclitaxel-eluting stent. MI = myocardial infarction. PCI = percutaneous
coronary intervention. CABG = coronary artery bypass graft. EF = ejection fraction.
DAPT = dual antiplatelet therapy.addition, although there were no signiﬁcant differences in thickness of
averaged NIT andminimal NIT between the two groups, the signiﬁcant-
ly higher thickness of maximum NIT in PES group resulted in the lower
NIT eccentricity index.
At cross-sectional level, NIT area in the EES group was signiﬁcantly
lower compared with the PES group (0.97 ± 0.42 mm2 vs. 1.27 ±
0.67 mm2; p = 0.01). In qualitative analysis, there was a signiﬁcantly
higher rate of homogeneous pattern of NIT with EES than with PES,
however, the rates of heterogenous pattern of NIT and peri-stent
ulcer-like appearance with EES were signiﬁcantly lower than with
PES. Intraluminal materials were rarely observed in the overall study
population.Table 2
Lesion characteristics and procedural results.
Variable EES (n = 50) PES (n = 50) p
Location of stent
LAD 19 (38%) 15 (30%) 0.53
LCX 16 (32%) 20 (40%)
RCA 15 (30%) 15 (30%)
Calciﬁcation 10 (20%) 7 (14%) 0.6
Bending 4 (8%) 4 (8%) N0.99
De novo lesion 47 (94%) 47 (94%) N0.99
Length of stent, mm 18 (12–23) 16 (12–20) 0.42
N20 mm stenting 14 (28%) 18 (36%) 0.52
Direct stenting 8 (16%) 9 (18%) N0.99
Maximum stent dilatation
pressure, atm
8 (8–12) 12 (10–15) b0.0001
Post dilatation 45 (90%) 29 (58%) 0.0005
Post dilatation balloon size, mm 2.75 (2.5–3.0) 2.75 (2.5–3.0) 0.95
Values are the numbers (%), mean ± SD, or median and interquartile ranges.
EES = everolimus-eluting stent. PES = paclitaxel-eluting stent. LAD = left anterior
descending artery. LCX = left circumﬂex artery. RCA = right coronary artery.
Table 3
Quantitative coronary angiography analysis.
Variable EES (n = 50) PES (n = 50) p
Pre-procedure
Lesion length, mm 14.6 ± 7.6 12.6 ± 6.6 0.16
Reference diameter, mm 2.28 ± 0.25 2.30 ± 0.26 0.73
Minimal luminal diameter, mm 0.87 ± 0.19 0.87 ± 0.24 0.96
Diameter stenosis, % 62.1 ± 8.7 62.2 ± 9.8 0.98
Post-procedure
Reference diameter, mm 2.52 ± 0.21 2.50 ± 0.23 0.61
Minimal luminal diameter, mm 2.32 ± 0.25 2.32 ± 0.21 0.98
Acute gain, mm 1.47 ± 0.37 1.45 ± 0.29 0.83
Diameter stenosis, % 8.2 ± 7.0 7.1 ± 7.1 0.47
Follow-up
Reference diameter, mm 2.44 ± 0.23 2.39 ± 0.22 0.28
Minimal luminal diameter, mm 1.94 ± 0.42 1.90 ± 0.41 0.65
Late loss, mm 0.38 ± 0.41 0.42 ± 0.36 0.61
Diameter stenosis, % 20.7 ± 14.7 20.8 ± 14.7 0.98
Values are the numbers (%) or mean ± SD.
EES = everolimus-eluting stent. PES = paclitaxel-eluting stent.
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homogeneous NIT frames in the EES group. Additionally, the rate of
stents with complete stent coverage and all homogeneous frames was
also signiﬁcantly higher in the EES group. On the other hand, the rate
of stents with any heterogenous NIT frame was signiﬁcantly lower
than the PES group.Fig. 2. Optical coherence tomography (OCT) ﬁndings of everolimus-eluting stent at 9 month fo
timal tissue was homogeneous and concentric.3.5. Reproducibility of qualitative OCT analysis
Interobserver/intraobserver variability (kappa values) for the quali-
tativeOCT analysis was as follows: 0.87/0.88 for NIT structure (homoge-
neous versus heterogeneous intima), 0.84/0.88 for peri-stent ulcer-like
appearance, 0.89/0.92 for thrombi.
4. Discussion
This study was a comparison of the vascular response evaluated by
OCT at 9 months betweenEES and PES for small coronary artery disease.
The main ﬁndings of this study were that (1) the OCT heterogeneous
pattern of NIT was more frequently observed in the PES group and the
OCT homogeneous pattern of NIT was more frequently observed in
EES, (2) the more concentric NIT was observed in EES, and (3) the
rates of exposed strut and malapposed strut after EES implantation
were lower than those after PES.
Percutaneous coronary intervention (PCI) in small coronary arteries
poses a greater procedural challenge compared to PCI in large vessels,
and higher rates of adverse cardiovascular events have been observed
in patients with small coronary artery disease even in the DES era
[16–18]. Large scale studies showed the clinical and angiographic supe-
riorities of EES over PES [19] and deﬁnite or probable stent thrombosis
increased after PES implantation for compared with EES [19]. It is well
known that delayed healing and incomplete endothelial cell coveragellow-up. There was no angiographic restenosis. In OCT ﬁndings, the morphology of neoin-
Fig. 3.Optical coherence tomography (OCT) ﬁndings of paclitaxel-eluting stent at 9 month follow-up. Therewasno angiographic restenosis. InOCTﬁndings, themorphology of neointimal
tissue was heterogeneous and eccentric.
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tion [20]. In a previous study, the percentage of exposed strut at
9 months follow-up was signiﬁcantly smaller in EES than sirolimus-
eluting stent, however, the percentage of malapposed strut was similar
between the two stent groups [21]. On the other hand, in this study,
lower exposed and malapposed stent strut rates with EES suggest the
clinical superiority to those of PES and several factorsmight be attribut-
able as follows. First, thedifference in the polymermight have an impact
on the vascular response. The nonthrombogenic ﬂuoropolymer is rela-
tively thin (8 μm) on the surface of the EES, on the other hand, PES is
covered with the thicker (17.8 μm) 3-layer styrene-isobutylene-
styrene polymer. Second, the difference in the drug may be associated
with various NIT growth. Although both everolimus and paclitaxel in-
hibit proliferation of smooth muscle cells and endothelial cells, only
paclitaxel disrupts migration of endothelial cells. In consequence, pacli-
taxel showed a higher cytotoxicity than everolimus.
On the other hand, therewas no signiﬁcant difference in angiographic
late loss and averaged thickness of NIT between the two stent groups. In
addition, a relatively higher NIT thickness in both stent groups were ob-
served compared with previous studies [10,11] including larger coronary
artery disease. However, maximum thickness of NIT in the PES groupwas
signiﬁcantly higher than that in the EES group. This differencewas associ-
ated with the differences of NIT eccentricity index (EES 0.69 ± 0.08 vs.
PES 0.76 ± 0.10, p = 0.001) and NIT area (EES 19.1 ± 8.3 mm2 vs. PES24.6 ± 13.6 mm2, p = 0.02) between the two stent groups. The clinical
signiﬁcance of NIT eccentricity has not been well established, however,
it may be associated with neo-atherosclerosis in NIT after DES implanta-
tion as eccentric lipid rich plaque in the native coronary artery which
can increase risk for instability [22]. From previous autopsy studies
[23,24], in-stent neoatherosclerosis after drug-eluting stent implantation
occurred at an earlier time point as comparedwith baremetal stents. Pre-
vious OCT studies showed that the duration after stent implantation was
associated with the progression of in-stent atherosclerotic change [25]
and a part of the heterogeneous pattern of NIT at 9 month follow-up
might change to the lipid-laden neointima at 2 year follow-up [26]. In
this study, heterogeneous NIT was observed more frequently in the PES
group at cross-sectional level analysis and half of the PES group included
at least one frame with heterogeneous NIT at stent level analysis. Thus,
NIT after EES implantation for small coronary artery disease showed a
more stable morphology at 9 month follow-up compared with PES.
These results also might be associated with the lower incidence of
major adverse cardiac events including deﬁnite or probable stent throm-
bosis after EES implantation compared with PES [19].
4.1. Limitations
This study was not randomized study and performed consecutively.
Therefore, some procedural characteristics were not matched between
Table 4
Quantitative and qualitative optical coherence tomography results.
Variable EES PES p
Strut level analysis
Number of stent strut 9705 7605
Exposed struts 23 (0.2%) 130 (1.7%) 0.0001
Malapposed struts 9 (0.1%) 60 (0.3%) 0.001
Averaged thickness of NIT, mm 0.13 ± 0.06 0.17 ± 00.09 0.05
Maximum thickness of NIT, mm 0.21 ± 0.08 0.30 ± 0.14 0.001
Minimal thickness of NIT, mm 0.07 ± 0.04 0.08 ± 0.06 0.5
NIT eccentricity index 0.69 ± 0.08 0.76 ± 0.10 0.001
Cross-sectional level analysis
Number of cross-sectional frame 859 825
Stent area, mm2 5.16 ± 1.05 5.29 ± 0.74 0.46
Lumen area, mm2 4.18 ± 1.03 4.03 ± 1.04 0.48
NIT area, mm2 0.97 ± 0.42 1.27 ± 0.67 0.01
% NIT area, % 19.1 ± 8.3 24.6 ± 13.6 0.02
Frame with homogeneous NIT 803 (93%) 737 (89%) 0.003
Frame with heterogeneous NIT 56 (6.5%) 88 (10.7%) 0.003
Frame with peri-stent ulcer-like appearance 36 (4.1%) 65 (7.9%) 0.002
Frame with thrombi 0 4 (0.5%) –
Stent level analysis
Number of stent 50 50
Stent with all homogeneous NIT frames 22 (44%) 8 (16%) 0.004
Stent with complete stent coverage and all homogeneous frames 20 (40%) 4 (8%) 0.0003
Stent with any heterogeneous NIT frame 12 (24%) 25 (50%) 0.01
Stent with the presence of thrombus 0 1 (2%) –
Values are the numbers (%) or mean ± SD.
EES = everolimus-eluting stent. NIT = neointimal tissue. PES = paclitaxel-eluting stent.
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technique for small coronary artery diseasesmight be different between
the two stent groups. The present study includes a small number of pa-
tients without in-stent restenosis. The association of long-term clinical
results including very late thrombosis and late catch-up in-stent reste-
nosis with OCT ﬁndings in this study could not be evaluated, due to a
single-point observation. Although the incidence of angiotensin
converting enzyme inhibitors (ACE-I) was not different between the
two stent groups and drug types of ACE-I were not evaluated in this
study, ACE-Imight have some effect of NIH formation after implantation
of PES and EES [27,28]. OCT analysis immediately after stent implanta-
tionwas not performed in this study. Histological data is required to val-
idate the sensitivity and speciﬁcity of OCT ﬁndings of NIT.
5. Conclusions
A more favorable vascular response was observed after EES implan-
tation compared with PES for small coronary artery disease. In addition,
the characteristics of NIT after EES implantation were more stable than
PES at 9 month follow-up examination.
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